Farringdon Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.06M Buy
2,549
+672
+36% +$687K 1.51% 20
2026
Q1
$1.73M Sell
1,877
-780
-29% -$791K 0.38% 85
2025
Q4
$2.86M Buy
2,657
+1,721
+184% +$1.65M 0.7% 29
2025
Q3
$714K Buy
936
+440
+89% +$327K 0.18% 171
2025
Q2
$387K Buy
+496
New +$385K 0.13% 266
2025
Q1
Sell
-1,236
Closed -$954K 489
2024
Q4
$954K Buy
+1,236
New +$1.02M 0.39% 48

Other funds holding LLY

Farringdon Capital's LLY Position: Q2 2026 in Review

Farringdon Capital increased its Eli Lilly (LLY) stake by 36% in Q2 2026, buying an estimated $687K and bringing the position to 2,549 shares worth $3.06M. The position accounts for 1.51% of the portfolio, ranked #20.

Farringdon Capital first reported a position in LLY in Q4 2024 and has held it in 6 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Farringdon Capital held 2,549 shares of Eli Lilly worth $3.06M as of Q2 2026.
  • Farringdon Capital bought 672 Eli Lilly shares in Q2 2026, an estimated $687K.
  • Eli Lilly made up 1.51% of Farringdon Capital's portfolio in Q2 2026, its #20 holding.
  • Farringdon Capital first reported a position in Eli Lilly in Q4 2024 and has held it in 6 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Farringdon Capital's 13F filing for Q2 2026, filed 12 Aug 2026.